Short-term consumption of oral omega-3 and dry eye syndrome
Kangari H, Eftekhari MH, Sardari S, Sardari S, Hashemi H, Salamzadeh J, Ghassemi-Broumand M, Khabazkhoob M
Ophthalmology · 82 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2013-05-01 · Ophthalmology · vol. 120 · número 11 · págs. 2191–2196
- Editorial
- Elsevier BV
- Citado
- 126 citas · más que el 99% de estudios similares · 12.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 26 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Ocular Surface and Contact Lens · Fatty Acid Research and Health · Retinal Diseases and Treatments
- Palabras clave
- omega-3 fatty acids, dry eye, eicosapentaenoic acid, docosahexaenoic acid, tear film break-up time, Schirmer test, Ocular Surface Disease Index, ocular surface disease, dietary supplementation, tear film stability, ocular lubrication, older adults
- MeSH
- tears, humans, dry eye syndromes, fatty acids, omega-3, docosahexaenoic acids, eicosapentaenoic acid, capsules, administration, oral, double-blind method, aged, aged, 80 and over, middle aged, female, male, surveys and questionnaires
7 autores
- Haleh Kangari🇮🇷Shahid Beheshti University; Shahid Beheshti University of Medical Sciences
- Mohammad Hossein Eftekhari🇮🇷Shahid Beheshti University of Medical Sciences
- Sara Sardari🇮🇷 · autor de correspondenciaShahid Beheshti University; Shahid Beheshti University of Medical Sciences
- Hassan Hashemi🇮🇷Noor Eye Hospital; Noor Ophthalmology Research Center
- Jamshid Salamzadeh🇮🇷Shahid Beheshti University of Medical Sciences
- Mohammad Ghassemi‐Broumand🇮🇷Shahid Beheshti University of Medical Sciences
- Mehdi Khabazkhoob🇮🇷Dezful University of Medical Sciences
Resumen
El texto original del estudio, en el idioma en que se publicó.
Purpose
To assess the effect of oral omega-3 fatty acids on tear break-up time (TBUT), Schirmer's score, and Ocular Surface Disease Index (OSDI) through a double-blind clinical trial.
Design
Randomized, double-blind clinical trial.
Participants
Sixty-four patients with dry eye symptoms between the ages of 45 and 90 years were randomized into 2 groups: 33 persons in the treatment group and 31 persons in the placebo group.
Methods
The treatment group received 2 capsules of omega-3 (each containing 180 mg eicosapentaenoic acid [EPA] and 120 mg docosahexaenoic acid [DHA]) daily for 30 days, and the placebo group received 2 medium-chain triglyceride oil capsules daily for 1 month. The outcomes were measured 1 month after the intervention.
Main outcome measures
The primary outcome measure was an increase from baseline in TBUT at day 30. Secondary outcome measures were a decrease from baseline in the OSDI score and an increase in the Schirmer's score at day 30.
Results
In the placebo group, before the intervention, the mean TBUT, OSDI, and Schirmer's scores were 4.5 ± 2.1 seconds, 36.4 ± 13.8, and 6.0 ± 2.6 mm, respectively, and 1 month later were 4.7 ± 2.6 seconds, 37.6 ± 13.5, and 6.2 ± 2.5 mm, respectively. In the treatment group, these values were 3.9 ± 1.7 seconds, 38.7 ± 16.5, and 5.8 ± 2.5 mm before the intervention and 5.67 ± 2.6 seconds, 29.3 ± 15.9, and 6.8 ± 2.8 mm after the intervention, respectively. Repeated-measures analysis of variance showed that improvements in TBUT, OSDI, and Schirmer's scores were significantly better in the treatment group than in the placebo group. The changes in the treatment and placebo groups were 71% and 3.3% for TBUT (P < 0.001), 26% and 4% (P=0.004) for dry eye symptoms, and 22.3% and 5.1% for Schirmer's score (P=0.033), respectively.
Conclusions
This study demonstrated that oral consumption of omega-3 fatty acids (180 mg EPA and 120 mg DHA twice daily for 30 days) is associated with a decrease in the rate of tear evaporation, an improvement in dry eye symptoms, and an increase in tear secretion.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.